Ocular Therapeutix, Inc.

OCUL

US67576A1007

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
4.745 ^USD	+12.98%		-9.10%	+6.39%

Apr. 18	Health Care Flat on Rotation From Rate-Sensitive Sectors -- Health Care Roundup	DJ
Apr. 18	Ocular Therapeutix Reports Positive Topline Data in Diabetic Retinopathy Trial; Shares Fall	MT

Ocular Therapeutix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023

March 11, 2024 at 04:05 pm EDT

Ocular Therapeutix, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 14.8 million compared to USD 14.08 million a year ago. Net loss was USD 29.22 million compared to USD 15.54 million a year ago.

Basic loss per share from continuing operations was USD 0.35 compared to USD 0.2 a year ago. Diluted loss per share from continuing operations was USD 0.35 compared to USD 0.24 a year ago.

Latest news about Ocular Therapeutix, Inc.

Health Care Flat on Rotation From Rate-Sensitive Sectors -- Health Care Roundup	Apr. 18	DJ
Ocular Therapeutix Reports Positive Topline Data in Diabetic Retinopathy Trial; Shares Fall	Apr. 18	MT
Ocular Therapeutix, Inc. Announces Positive Topline Phase 1 Data for AXPAXLI? in Diabetic Retinopathy	Apr. 18	CI
Ocular Therapeutix CEO Antony Mattessich Steps Down; Pravin Dugel Named Successor	Apr. 15	MT
Ocular Therapeutix, Inc. Announces Executive Changes	Apr. 15	CI
Ocular Therapeutix, Inc. Announces CEO Changes	Apr. 15	CI
Ocular Therapeutix, Inc. Announces Positive Phase 2 PAXTRAVA? Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting	Apr. 06	CI
Ocular Therapeutix Files Shelf for Common Stock Sale by Stockholders; Shares Fall After Hours	Mar. 25	MT
Ocular Therapeutix, Inc.(NasdaqGM:OCUL) added to S&P Pharmaceuticals Select Industry Index	Mar. 17	CI
HC Wainwright Adjusts Price Target on Ocular Therapeutix to $15 From $12, Keeps Buy Rating	Mar. 13	MT
TD Cowen Adjusts Price Target on Ocular Therapeutix to $11 From $8, Maintains Market Perform Rating	Mar. 12	MT
JMP Securities Adjusts Ocular Therapeutix's Price Target to $24 From $12, Maintains Market Outperform Rating	Mar. 12	MT
Ocular Therapeutix Q4 Loss Widens, Revenue Rises -- Shares Down After Hours	Mar. 11	MT
Ocular Therapeutix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 11	CI
Earnings Flash (OCUL) OCULAR THERAPEUTIX Posts Q4 Revenue $14.8M, vs. Street Est of $15.7M	Mar. 11	MT
Ocular Therapeutix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 11	CI
North American Morning Briefing : Stock Futures -2-	Mar. 11	DJ
Ocular Therapeutix, Inc. announced that it has received $324.999962 million in funding from a group of investors	Mar. 04	CI
Piper Sandler Adjusts Ocular Therapeutix Price Target to $15 From $10, Maintains Overweight Rating	Feb. 26	MT
Ocular Therapeutix Launches $325 Million Private Placement; Makes Board, Management Changes, Shares Rise	Feb. 22	MT
Ocular Therapeutix, Inc. Announces Management Changes	Feb. 22	CI
Ocular Therapeutix, Inc. announced that it expects to receive $324.999962 million in funding	Feb. 20	CI
AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority for DEXTENZA	Feb. 19	CI
Ocular Therapeutix, Inc. Appoints Steve Meyers as Chief Commercial Officer	Feb. 15	CI
Ocular Therapeutix Says First Subjects Screened in Phase 3 Clinical Trial of Wet AMD Treatment	Feb. 13	MT

Chart Ocular Therapeutix, Inc.

Duration

Period

More charts

Company Profile

Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye. Its first commercial drug product, DEXTENZA, is for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. It is also developing two other clinical-stage assets, OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease, and OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease. It is conducting a pivotal Phase III clinical trial to evaluate AXPAXLI for the treatment of wet AMD. Its clinical portfolio also includes PAXTRAVA, which is in Phase III clinical development for the treatment of primary open-angle glaucoma (OAG) or ocular hypertension (OHT).

Sector

Pharmaceuticals

Calendar

2024-05-09 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Ocular Therapeutix, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.745 USD

Average target price

15.5 USD

Spread / Average Target

+226.66%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
OCULAR THERAPEUTIX, INC.	+6.39%	734M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals